{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:39:45Z","timestamp":1777052385094,"version":"3.51.4"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Autologous stem cell transplantation has proven to be beneficial in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). In patients with HD, transplantation appears to increase event-free survival in patients who fail to enter complete remission with initial therapy. When a patient relapses after a complete remission, transplantation is probably the best option and particularly so if the remission lasted less than 1 year. Transplantation as part of primary therapy for very high-risk patients may be beneficial, but is not standard therapy at this time. For patients with diffuse large-cell NHL, transplantation can be considered standard therapy for relapsed patients if they have chemotherapy-sensitive disease. The use of transplantation for high-risk patients in complete remission is promising, but definite recommendations cannot be made at this time. For follicular lymphomas, selected patients seem to benefit and studies are ongoing. Finally, the use of allogeneic stem cell transplantation can be useful in a select group of younger patients.<\/jats:p>","DOI":"10.1634\/theoncologist.6-3-247","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"247-256","source":"Crossref","is-referenced-by-count":26,"title":["High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma"],"prefix":"10.1093","volume":"6","author":[{"given":"Scott A.","family":"Mink","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center, Section of Oncology\/Hematology, Omaha, Nebraska, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Section of Oncology\/Hematology, Omaha, Nebraska, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,6,1]]},"reference":[{"key":"2021122210295468200_R1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","article-title":"Cancer Statistics, 2000","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"2021122210295468200_R2","first-page":"952","volume-title":"Hematopoietic Cell Transplantation","author":"Bierman","year":"1999","edition":"2nd Edition"},{"key":"2021122210295468200_R3","first-page":"2447","volume-title":"Wintrobe's Clinical Hematology","author":"Greer","year":"1999","edition":"Tenth Edition"},{"key":"2021122210295468200_R4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1083-8791(99)70010-8","article-title":"Historical markers in the development of allogeneic hematopoietic cell transplantation","volume":"5","author":"Thomas","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122210295468200_R5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.V52.1.85.85","article-title":"Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma","volume":"52","author":"Appelbaum","year":"1978","journal-title":"Blood"},{"key":"2021122210295468200_R6","first-page":"4","article-title":"New summary slides show current trends in BMT","volume":"5","author":"Rizzo","year":"1998","journal-title":"Autologous Blood and Marrow Transplant Registry Newsletter"},{"key":"2021122210295468200_R7","first-page":"482","volume-title":"Clinical Oncology","author":"Vose","year":"2000","edition":"Second Edition"},{"key":"2021122210295468200_R8","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1083-8791(00)70047-4","article-title":"A review of autologous hematopoietic cell transplantation","volume":"6","author":"Blume","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122210295468200_R10","first-page":"77","volume-title":"eds. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells","author":"Yahalom","year":"2000","edition":"Third Edition"},{"key":"2021122210295468200_R11","first-page":"775","volume-title":"eds. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells","author":"Chakraverty","year":"2000","edition":"Third Edition"},{"key":"2021122210295468200_R12","first-page":"192","article-title":"Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells","volume":"14","author":"Kessinger","year":"1986","journal-title":"Exp Hematol"},{"key":"2021122210295468200_R13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1182\/blood.V71.3.723.723","article-title":"Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy","volume":"71","author":"Kessinger","year":"1988","journal-title":"Blood"},{"key":"2021122210295468200_R14","first-page":"40","article-title":"Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia","volume":"20","author":"Juttner","year":"1988","journal-title":"Transplant Proc"},{"key":"2021122210295468200_R15","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood.V74.6.1905.1905","article-title":"Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor","volume":"74","author":"Siena","year":"1989","journal-title":"Blood"},{"key":"2021122210295468200_R16","first-page":"442","article-title":"Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood [see comments]","volume":"18","author":"To","year":"1990","journal-title":"Exp Hematol"},{"key":"2021122210295468200_R17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/0140-6736(92)90795-5","article-title":"Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy [see comments]","volume":"339","author":"Sheridan","year":"1992","journal-title":"Lancet"},{"key":"2021122210295468200_R18","first-page":"2491","article-title":"A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients","volume":"93","author":"Shpall","year":"1999","journal-title":"Blood"},{"key":"2021122210295468200_R19","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1200\/JCO.1997.15.9.3067","article-title":"Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies","volume":"15","author":"Brown","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(96)90536-X","article-title":"Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients [see comments] [published erratum appears in Lancet 1996;347:914]","volume":"347","author":"Schmitz","year":"1996","journal-title":"Lancet"},{"key":"2021122210295468200_R21","first-page":"211","volume-title":"Clinical Bone Marrow and Blood Stem Cell Transplantation","author":"Bierman","year":"2000","edition":"Second Edition"},{"key":"2021122210295468200_R22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.1996.14.1.214","article-title":"Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest","volume":"14","author":"Sharp","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R23","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJM199111283252201","article-title":"Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma [see comments]","volume":"325","author":"Gribben","year":"1991","journal-title":"N Engl J Med"},{"key":"2021122210295468200_R24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/11.suppl_1.S91","article-title":"The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)","volume":"11","author":"Schouten","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122210295468200_R25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1992.10.2.210","article-title":"Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure","volume":"10","author":"Longo","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.1997.15.2.528","article-title":"Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD [see comments]","volume":"15","author":"Bonfante","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V89.3.814","article-title":"Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease","volume":"89","author":"Yuen","year":"1997","journal-title":"Blood"},{"key":"2021122210295468200_R28","first-page":"486a","article-title":"Thirty percent of adult patients with primary refractory Hodgkin's disease (HD) are progression free at 5 years after high dose therapy (HDT) and autologous stem cell transplantation (ASCT): data from 290 patients reported to the EBMT","volume":"88","author":"Sweetenham","year":"1996","journal-title":"Blood"},{"key":"2021122210295468200_R29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","article-title":"The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patients","volume":"81","author":"Chopra","year":"1993","journal-title":"Blood"},{"key":"2021122210295468200_R30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V86.2.451.bloodjournal862451","article-title":"High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV \u00b1 P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy","volume":"86","author":"Reece","year":"1995","journal-title":"Blood"},{"key":"2021122210295468200_R31","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.1993.11.6.1062","article-title":"Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease","volume":"11","author":"Yahalom","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R32","first-page":"486a","article-title":"Early intensive therapy with autologous stem cell transplantation (ASCT) in high-risk Hodgkin's disease (HD): report of 158 cases from the French registry (SFGM)","volume":"88","author":"Moreau","year":"1996","journal-title":"Blood"},{"key":"2021122210295468200_R33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/oxfordjournals.annonc.a058399","article-title":"High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease\u2014a 6-year update","volume":"4","author":"Gianni","year":"1993","journal-title":"Ann Oncol"},{"key":"2021122210295468200_R34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"2021122210295468200_R35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/oxfordjournals.annonc.a010542","article-title":"High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy","volume":"7","author":"Bierman","year":"1996","journal-title":"Ann Oncol"},{"key":"2021122210295468200_R36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V83.5.1193.1193","article-title":"Intensive therapy with cyclophosphamide, carmustine, etoposide \u00b1 cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy [see comments]","volume":"83","author":"Reece","year":"1994","journal-title":"Blood"},{"key":"2021122210295468200_R37","first-page":"99","article-title":"Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP\/ABVD protocol","volume":"8","author":"Carella","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"2021122210295468200_R38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/10428199609067581","article-title":"Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP\/ABVD chemotherapy","volume":"21","author":"Carella","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"2021122210295468200_R39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.bmt.1700886","article-title":"Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group","volume":"20","author":"Sureda","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2021122210295468200_R40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/10428199909050955","article-title":"Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome","volume":"34","author":"Delain","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"2021122210295468200_R41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10428199609051616","article-title":"High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease","volume":"20","author":"Fleury","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"2021122210295468200_R42","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.7326\/0003-4819-114-12-1059","article-title":"Autotransplantation in lymphoma: better therapy or healthier patients? [editorial]","volume":"114","author":"Surbone","year":"1991","journal-title":"Ann Intern Med"},{"key":"2021122210295468200_R43","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"key":"2021122210295468200_R44","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.1990.8.4.630","article-title":"The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas","volume":"8","author":"Colombat","year":"1990","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R45","first-page":"135","article-title":"Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging","volume":"8","author":"Weisdorf","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"2021122210295468200_R46","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.1992.10.11.1682","article-title":"High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma","volume":"10","author":"Lazarus","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R47","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1200\/JCO.1993.11.10.1846","article-title":"High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma [see comments]","volume":"11","author":"Vose","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R48","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1200\/JCO.1993.11.6.1085","article-title":"Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide","volume":"11","author":"Wheeler","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R49","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R50","first-page":"549","article-title":"High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity","volume":"15","author":"Besien","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2021122210295468200_R51","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood.V90.8.2921","article-title":"High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry","volume":"90","author":"Ladenstein","year":"1997","journal-title":"Blood"},{"key":"2021122210295468200_R52","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/JCO.1990.8.4.638","article-title":"Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle","volume":"8","author":"Petersen","year":"1990","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bmt.1700772","article-title":"Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors","volume":"19","author":"Rapoport","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2021122210295468200_R54","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V75.4.831.831","article-title":"The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation","volume":"75","author":"Phillips","year":"1990","journal-title":"Blood"},{"key":"2021122210295468200_R55","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.1994.12.12.2559","article-title":"High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma","volume":"12","author":"Weaver","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R56","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [see comments]","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122210295468200_R57","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.1998.16.10.3264","article-title":"Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial","volume":"16","author":"Guglielmi","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R58","first-page":"3562","article-title":"The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"key":"2021122210295468200_R59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1999.17.1.423","article-title":"International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury","volume":"17","author":"Shipp","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R60","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol\u2014a groupe d'Etude des lymphomes de l'Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R61","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group","volume":"16","author":"Santini","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R62","first-page":"594a","article-title":"Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: updated results of the randomized LNH93-3 study","volume":"90","author":"Reyes","year":"1997","journal-title":"Blood"},{"key":"2021122210295468200_R63","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma [see comments]","volume":"332","author":"Verdonck","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122210295468200_R64","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Haioun","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1200\/JCO.1987.5.3.407","article-title":"Results of MIME salvage regimen for recurrent or refractory lymphoma","volume":"5","author":"Cabanillas","year":"1987","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R66","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R67","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.V77.11.2524.2524","article-title":"Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma","volume":"77","author":"Freedman","year":"1991","journal-title":"Blood"},{"key":"2021122210295468200_R68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.1991.tb01539.x","article-title":"Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin's lymphoma","volume":"46","author":"Fouillard","year":"1991","journal-title":"Eur J Haematol"},{"key":"2021122210295468200_R69","first-page":"157","article-title":"Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients","volume":"13","author":"Colombat","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"2021122210295468200_R70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/5.suppl_2.S147","article-title":"Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. EBMT Working Party for Lymphoma","volume":"5","author":"Schouten","year":"1994","journal-title":"Ann Oncol"},{"key":"2021122210295468200_R71","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma","volume":"12","author":"Rohatiner","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R72","first-page":"387","article-title":"Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma","volume":"16","author":"Cervantes","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2021122210295468200_R73","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","article-title":"Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma","volume":"86","author":"Bastion","year":"1995","journal-title":"Blood"},{"key":"2021122210295468200_R74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","article-title":"High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma","volume":"15","author":"Bierman","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R75","first-page":"500","volume-title":"Clinical Bone Marrow and Blood Stem Cell Transplantation","author":"Phillips","year":"2000","edition":"Second Edition"},{"key":"2021122210295468200_R76","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"2021122210295468200_R77","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R78","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R79","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"Besien","year":"1998","journal-title":"Blood"},{"key":"2021122210295468200_R80","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"2021122210295468200_R81","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies [see comments]","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122210295468200_R82","first-page":"47a","article-title":"\u201cMini\u201d-allogeneic stem cell transplanationa for relapsed\/refractory lymphomas with aggressive histologies","volume":"19","author":"Khouri","year":"2000","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.6-3-247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.6-3-247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/3\/247\/41837686\/oncolo_6_3_247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/3\/247\/41837686\/oncolo_6_3_247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T18:23:07Z","timestamp":1640197387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/6\/3\/247\/6386886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2001,6,1]]},"published-print":{"date-parts":[[2001,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.6-3-247","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,6,1]]},"published":{"date-parts":[[2001,6,1]]}}}